TISEO, Marcello
TISEO, Marcello
Dipartimento di Medicina e Chirurgia
"Pseudocavitation" in thymic carcinoma during treatment with sunitinib
2013-01-01 Tiseo, M.; Rajan, A.; Thomas, A.; Giaccone, G.
'Turban-like' skull metastasis from pulmonary adenocarcinoma
2017-01-01 Mengoli, M. C.; Rossi, G.; Tiseo, M.; Barbieri, F.; Pifferi, M.; Bertolini, F.; Lococo, F.
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC
2022-01-01 Mazzaschi, G.; Moron Dalla Tor, L.; Balbi, M.; Milanese, G.; Tognazzi, D.; Lorusso, B.; Trentini, F.; Di Rienzo, G.; Verzè, M.; Pluchino, M.; Minari, R.; Leo, L.; Gnetti, L.; Bordi, P.; Leonetti, A.; Ampollini, L.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients
2024-01-01 Mazzaschi, G.; Marrocchio, C.; Moron Dalla Tor, L.; Leo, L.; Dodi, A.; Tamarozzi, P.; Balbi, M.; Milanese, G.; Monica, G.; D'Agnelli, S.; Lorusso, B.; Pluchino, M.; Minari, R.; Leonetti, A.; Bordi, P.; Perrone, F.; Buti, S.; Quaini, F.; Roti, G.; Sverzellati, N.; Tiseo, M.
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy
2021-01-01 Mazzaschi, G.; Scandino, R.; Milanese, G.; Pavone, C.; Maurizio, B.; Silva, M.; Ledda, R.; Minari, R.; Trentini, F.; Buti, S.; Bordi, P.; Leonetti, A.; Quaini, F.; Sverzellati, N.; Romanel, A.; Tiseo, M.
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study
2023-01-01 Leonetti, Null; Peroni, M.; Agnetti, V.; Pratticò, F.; Manini, M.; Acunzo, A.; Marverti, F.; Sulas, S.; Rapacchi, E.; Mazzaschi, G.; Perrone, F.; Bordi, P.; Buti, S.; Tiseo, M.
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients
2021-01-01 Mazzaschi, G.; Milanese, G.; Moron Dalla Tor, L.; Leo, L.; Balbi, M.; Trentini, F.; Manini, M.; Pavone, C.; Silva, M.; Ledda, R. E.; Minari, R.; Bordi, P.; Buti, S.; Leonetti, A.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC
2023-01-01 Mazzaschi, G.; Bocchialini, G.; Lorusso, B.; Pluchino, M.; Trentini, F.; Di Rienzo, G.; Cattadori, S.; Tor, L. Moron Dalla; Verzè, M.; Minari, R.; Bordi, P.; Leonetti, A.; D’Agnelli, S.; Milanese, G.; Leo, L.; Gnetti, L.; Roti, G.; Ampollini, L.; Quaini, F.; Sverzellati, N.; Tiseo, M.
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients
2020-01-01 Mazzaschi, G.; Minari, R.; Ferri, V.; Bordi, P.; Gnetti, L.; Bersanelli, M.; Cavazzoni, A.; Buti, S.; Leonetti, A.; Zecca, A.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Mori, C.; Petronini, P. G.; Missale, G.; Quaini, F.; Tiseo, M.
209P: SMO mutation is a strong negative prognostic factor in malignant pleural mesothelioma
2016-01-01 Signorelli, D.; Proto, C.; Ganzinelli, M.; Russo, G. L.; Botta, L.; Trama, A.; Pasello, G.; Tiseo, M.; Pelosi, G.; Garassino, M.
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study
2023-01-01 Cortellini, A.; Leonetti, A.; Parisi, A.; Tiseo, M.; Bordi, P.; Michiara, M.; Bui, S.; Cosenza, A.; Ferri, L.; Giudice, G. C.; Testi, I.; Vincenzi, B.; Santo, V.; Ricozzi, V.; Sgargi, P.; Zustovich, F.; Stucci, L. S.; Santini, D.; Buti, S.; Bersanelli, M.
227P Sexual dimorphism in immune profile of early and advanced NSCLC
2024-01-01 Mazzaschi, G.; Indries, P.; Monica, G.; Pluchino, M.; Lorusso, B.; D'Agnelli, S.; Bocchialini, G.; Trentini, F.; Dalla Tor, L. Moron; Verzè, M.; Minari, R.; Perrone, F.; Bordi, P.; Leonetti, A.; Gnetti, L.; Ampollini, L.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients
2023-01-01 Mazzaschi, G.; Cardinale, E.; Pluchino, M.; Monica, G.; Lorusso, B.; D'Agnelli, S.; Trentini, F.; Tamarozzi, P.; Dalla Tor, L. Moron; Verzè, M.; Minari, R.; Bordi, P.; Perrone, F.; Leonetti, A.; Gnetti, L.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors
2022-01-01 Mazzaschi, G.; Tamarozzi, P.; Lorusso, B.; Verzè, M.; Pluchino, M.; Trentini, F.; Dalla Valle, B.; Minari, R.; Perrone, F.; Bordi, P.; Leonetti, A.; Moron Dalla Tor, L.; Leo, L.; Milanese, G.; Balbi, M.; Buti, S.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC
2016-01-01 Bordi, P.; Del Re, M.; Danesi, R.; Tiseo, M.
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC
2023-01-01 Mazzaschi, G.; Barbieri, M.; Monica, G.; Pluchino, M.; Lorusso, B.; D'Agnelli, S.; Verzè, M.; Minari, R.; Perrone, F.; Bordi, P.; Leonetti, A.; Quaini, F.; Sverzellati, N.; Tiseo, M.
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients
2021-01-01 Mazzaschi, G.; Minari, R.; Gnetti, L.; Campanini, N.; Zielli, T.; Baucina, M.; Perrone, F.; Leonetti, A.; Quaini, F.; Tiseo, M.
9P Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model
2023-01-01 Mazzaschi, G.; Dos Santos, M.; Bergeron, P.; Sitterle, L.; Gérbé de Thoré, M.; Liu, W.; Clémenson, C.; Meziani, L.; Bawa, O.; Leroy, A.; Sun, R.; Moron Dalla Tor, L.; Quaini, F.; Tiseo, M.; Milliat, F.; Robert, C.; Mondini, M.; Deutsch, E.
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?
2021-01-01 Leonetti, A.; Carbone, D.; Gregori, A.; Tiseo, M.; Peters, G. J.; Deng, D.; Giovannetti, E.
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome
2024-01-01 Cognigni, Valeria; Capelletto, Enrica; Bordi, Paola; Pavese, Valeria; Carfì, Federica Maria; Gelsomino, Francesco; De Giglio, Andrea; Chiari, Rita; Minari, Roberta; Ambrosini, Enrico; Percesepe, Antonio; Giachino, Daniela; Bironzo, Paolo; Tiseo, Marcello
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| "Pseudocavitation" in thymic carcinoma during treatment with sunitinib | 1-gen-2013 | Tiseo, M.; Rajan, A.; Thomas, A.; Giaccone, G. | |
| 'Turban-like' skull metastasis from pulmonary adenocarcinoma | 1-gen-2017 | Mengoli, M. C.; Rossi, G.; Tiseo, M.; Barbieri, F.; Pifferi, M.; Bertolini, F.; Lococo, F. | |
| 1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC | 1-gen-2022 | Mazzaschi, G.; Moron Dalla Tor, L.; Balbi, M.; Milanese, G.; Tognazzi, D.; Lorusso, B.; Trentini, F.; Di Rienzo, G.; Verzè, M.; Pluchino, M.; Minari, R.; Leo, L.; Gnetti, L.; Bordi, P.; Leonetti, A.; Ampollini, L.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| 1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients | 1-gen-2024 | Mazzaschi, G.; Marrocchio, C.; Moron Dalla Tor, L.; Leo, L.; Dodi, A.; Tamarozzi, P.; Balbi, M.; Milanese, G.; Monica, G.; D'Agnelli, S.; Lorusso, B.; Pluchino, M.; Minari, R.; Leonetti, A.; Bordi, P.; Perrone, F.; Buti, S.; Quaini, F.; Roti, G.; Sverzellati, N.; Tiseo, M. | |
| 1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy | 1-gen-2021 | Mazzaschi, G.; Scandino, R.; Milanese, G.; Pavone, C.; Maurizio, B.; Silva, M.; Ledda, R.; Minari, R.; Trentini, F.; Buti, S.; Bordi, P.; Leonetti, A.; Quaini, F.; Sverzellati, N.; Romanel, A.; Tiseo, M. | |
| 1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study | 1-gen-2023 | Leonetti, Null; Peroni, M.; Agnetti, V.; Pratticò, F.; Manini, M.; Acunzo, A.; Marverti, F.; Sulas, S.; Rapacchi, E.; Mazzaschi, G.; Perrone, F.; Bordi, P.; Buti, S.; Tiseo, M. | |
| 17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients | 1-gen-2021 | Mazzaschi, G.; Milanese, G.; Moron Dalla Tor, L.; Leo, L.; Balbi, M.; Trentini, F.; Manini, M.; Pavone, C.; Silva, M.; Ledda, R. E.; Minari, R.; Bordi, P.; Buti, S.; Leonetti, A.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| 189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC | 1-gen-2023 | Mazzaschi, G.; Bocchialini, G.; Lorusso, B.; Pluchino, M.; Trentini, F.; Di Rienzo, G.; Cattadori, S.; Tor, L. Moron Dalla; Verzè, M.; Minari, R.; Bordi, P.; Leonetti, A.; D’Agnelli, S.; Milanese, G.; Leo, L.; Gnetti, L.; Roti, G.; Ampollini, L.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| 1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients | 1-gen-2020 | Mazzaschi, G.; Minari, R.; Ferri, V.; Bordi, P.; Gnetti, L.; Bersanelli, M.; Cavazzoni, A.; Buti, S.; Leonetti, A.; Zecca, A.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Mori, C.; Petronini, P. G.; Missale, G.; Quaini, F.; Tiseo, M. | |
| 209P: SMO mutation is a strong negative prognostic factor in malignant pleural mesothelioma | 1-gen-2016 | Signorelli, D.; Proto, C.; Ganzinelli, M.; Russo, G. L.; Botta, L.; Trama, A.; Pasello, G.; Tiseo, M.; Pelosi, G.; Garassino, M. | |
| 2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study | 1-gen-2023 | Cortellini, A.; Leonetti, A.; Parisi, A.; Tiseo, M.; Bordi, P.; Michiara, M.; Bui, S.; Cosenza, A.; Ferri, L.; Giudice, G. C.; Testi, I.; Vincenzi, B.; Santo, V.; Ricozzi, V.; Sgargi, P.; Zustovich, F.; Stucci, L. S.; Santini, D.; Buti, S.; Bersanelli, M. | |
| 227P Sexual dimorphism in immune profile of early and advanced NSCLC | 1-gen-2024 | Mazzaschi, G.; Indries, P.; Monica, G.; Pluchino, M.; Lorusso, B.; D'Agnelli, S.; Bocchialini, G.; Trentini, F.; Dalla Tor, L. Moron; Verzè, M.; Minari, R.; Perrone, F.; Bordi, P.; Leonetti, A.; Gnetti, L.; Ampollini, L.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| 2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients | 1-gen-2023 | Mazzaschi, G.; Cardinale, E.; Pluchino, M.; Monica, G.; Lorusso, B.; D'Agnelli, S.; Trentini, F.; Tamarozzi, P.; Dalla Tor, L. Moron; Verzè, M.; Minari, R.; Bordi, P.; Perrone, F.; Leonetti, A.; Gnetti, L.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| 238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors | 1-gen-2022 | Mazzaschi, G.; Tamarozzi, P.; Lorusso, B.; Verzè, M.; Pluchino, M.; Trentini, F.; Dalla Valle, B.; Minari, R.; Perrone, F.; Bordi, P.; Leonetti, A.; Moron Dalla Tor, L.; Leo, L.; Milanese, G.; Balbi, M.; Buti, S.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| 2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC | 1-gen-2016 | Bordi, P.; Del Re, M.; Danesi, R.; Tiseo, M. | |
| 5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC | 1-gen-2023 | Mazzaschi, G.; Barbieri, M.; Monica, G.; Pluchino, M.; Lorusso, B.; D'Agnelli, S.; Verzè, M.; Minari, R.; Perrone, F.; Bordi, P.; Leonetti, A.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| 7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients | 1-gen-2021 | Mazzaschi, G.; Minari, R.; Gnetti, L.; Campanini, N.; Zielli, T.; Baucina, M.; Perrone, F.; Leonetti, A.; Quaini, F.; Tiseo, M. | |
| 9P Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model | 1-gen-2023 | Mazzaschi, G.; Dos Santos, M.; Bergeron, P.; Sitterle, L.; Gérbé de Thoré, M.; Liu, W.; Clémenson, C.; Meziani, L.; Bawa, O.; Leroy, A.; Sun, R.; Moron Dalla Tor, L.; Quaini, F.; Tiseo, M.; Milliat, F.; Robert, C.; Mondini, M.; Deutsch, E. | |
| A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients? | 1-gen-2021 | Leonetti, A.; Carbone, D.; Gregori, A.; Tiseo, M.; Peters, G. J.; Deng, D.; Giovannetti, E. | |
| A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome | 1-gen-2024 | Cognigni, Valeria; Capelletto, Enrica; Bordi, Paola; Pavese, Valeria; Carfì, Federica Maria; Gelsomino, Francesco; De Giglio, Andrea; Chiari, Rita; Minari, Roberta; Ambrosini, Enrico; Percesepe, Antonio; Giachino, Daniela; Bironzo, Paolo; Tiseo, Marcello |